sunitinib stada kõvakapsel
stada arzneimittel ag - sunitiniib - kõvakapsel - 12,5mg 30tk
sunitinib stada kõvakapsel
stada arzneimittel ag - sunitiniib - kõvakapsel - 25mg 28tk; 25mg 30tk
sunitinib viasana kõvakapsel
viasana uab - sunitiniib - kõvakapsel - 25mg 30tk
sunitinib viasana kõvakapsel
viasana uab - sunitiniib - kõvakapsel - 50mg 30tk
sunitinib viasana kõvakapsel
viasana uab - sunitiniib - kõvakapsel - 12,5mg 30tk
suphrex kõvakapsel
lv system service sia - sunitiniib - kõvakapsel - 12,5mg 30tk
suphrex kõvakapsel
lv system service sia - sunitiniib - kõvakapsel - 50mg 30tk; 50mg 28tk
orserdu
stemline therapeutics b.v. - elacestrant - rinnanäärmed - endokriinset ravi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.